WASHINGTON TRUST Co Acquires 98 Shares of Eli Lilly and Company (NYSE:LLY)

WASHINGTON TRUST Co raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,459 shares of the company’s stock after buying an additional 98 shares during the quarter. WASHINGTON TRUST Co’s holdings in Eli Lilly and Company were worth $17,240,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Twin Peaks Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 3.2% during the 3rd quarter. Twin Peaks Wealth Advisors LLC now owns 735 shares of the company’s stock worth $651,000 after purchasing an additional 23 shares during the period. Pathway Financial Advisers LLC grew its position in Eli Lilly and Company by 92,759.9% during the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company’s stock worth $905,774,000 after buying an additional 1,021,287 shares in the last quarter. WD Rutherford LLC increased its stake in Eli Lilly and Company by 17.1% during the third quarter. WD Rutherford LLC now owns 274 shares of the company’s stock valued at $243,000 after acquiring an additional 40 shares during the period. Adell Harriman & Carpenter Inc. raised its holdings in Eli Lilly and Company by 19.6% in the 3rd quarter. Adell Harriman & Carpenter Inc. now owns 11,659 shares of the company’s stock valued at $10,330,000 after acquiring an additional 1,910 shares in the last quarter. Finally, Childress Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 4.5% during the 3rd quarter. Childress Capital Advisors LLC now owns 2,445 shares of the company’s stock worth $2,166,000 after purchasing an additional 105 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Barclays increased their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Stock Down 6.3 %

NYSE:LLY opened at $846.90 on Thursday. The company has a market cap of $804.90 billion, a price-to-earnings ratio of 124.73, a P/E/G ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock’s fifty day moving average price is $916.20 and its two-hundred day moving average price is $865.10. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.53 by ($0.35). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. On average, analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.